hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06262776, orgStudyIdInfo id: SIRZOSTER1.01, briefTitle: Safety and Immunogenicity of Recombinant Zoster Vaccine for Kidney Transplant Recipients, acronym: SIR ZOSTER, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2026-11, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Central Adelaide Local Health Network Incorporated, class: OTHER_GOV, collaborators name: National Health and Medical Research Council, Australia, collaborators name: University of Adelaide, collaborators name: Royal Prince Alfred Hospital, Sydney, Australia, descriptionModule briefSummary: The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between kidney transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are:1. Are there differences in vaccination immunological responses in kidney transplant patients on different immunosuppression regimens?2. Are there differences in vaccination immunological responses between kidney transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination., conditionsModule conditions: Immunosuppression, conditions: Vaccine Response Impaired, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Recombinant zoster vaccine adjuvanted (SHINGRIX), outcomesModule primaryOutcomes measure: Functional T cell memory, secondaryOutcomes measure: Frequency of virus specific T cells, secondaryOutcomes measure: Magnitude of antibody response, secondaryOutcomes measure: Concentration of post-vaccination circulating cytokines, secondaryOutcomes measure: Frequency of polyfunctional T cells, secondaryOutcomes measure: Magnitude of vaccine-induced cross-protective antiviral responses, secondaryOutcomes measure: Frequency of virus-specific T stem cell memory compared to baseline, otherOutcomes measure: Incidence of shingles, otherOutcomes measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, otherOutcomes measure: Tolerability of vaccination regimen as assessed by EQ-5D, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06262763, orgStudyIdInfo id: HILT for SIJP, briefTitle: High-intensity Laser Therapy for Sacroiliac Joint Pain, acronym: Girls, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-01-03, primaryCompletionDateStruct date: 2023-04-28, completionDateStruct date: 2024-03-28, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Kafrelsheikh University, class: OTHER, descriptionModule briefSummary: Effect of high intensity laser on sacroiliac joint pain, conditionsModule conditions: Sacroiliac Joint Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Laser Therapy, interventions name: Traditional exercises, interventions name: Placebo laser, outcomesModule primaryOutcomes measure: Pain intensity, secondaryOutcomes measure: Pressure pain threshold, otherOutcomes measure: Functional disability, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Kafr Al-Sheikh University, city: Kafr Ash Shaykh, country: Egypt, geoPoint lat: 31.11174, lon: 30.93991, hasResults: False
protocolSection identificationModule nctId: NCT06262750, orgStudyIdInfo id: 00375/23, briefTitle: Evaluation of Safety and Efficacy of Anticoagulation Treatment in Patients With Splanchnic Vein Thrombosis: SAPIENT Study, acronym: SAPIENT, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2023-12-01, completionDateStruct date: 2025-11-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: Prospective single-centre, observational study with medical products. Patients with a medical history of SVT will be observed for at least 24 months after inclusion. The study will begin when the patient is referred to our centre for SVT and will end at the 24-month follow-up or at the occurrence of a study outcome event, or in case of Death OBJECTIVE: To prospectively define the incidence of recurrent thrombosis and bleeding events during anticoagulant therapy in patients with diagnosed SVT, regardless of whether they will be hospitalized or treated as outpatients, conditionsModule conditions: Splanchnic Vein Thrombosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 170, type: ESTIMATED, outcomesModule primaryOutcomes measure: Incidenze of bleedings events, primaryOutcomes measure: Incidence of venous and arterial thromboembolic events, primaryOutcomes measure: Rate of progress /stable /regressive, primaryOutcomes measure: incidence of liver related events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UOC Servizio e DH Ematologia, status: RECRUITING, city: Rome, zip: 00168, country: Italy, contacts name: Valerio De Stefano, role: CONTACT, contacts name: Rossella Talerico, role: SUB_INVESTIGATOR, contacts name: Silvia Betti, role: SUB_INVESTIGATOR, contacts name: Francesco Santopaolo, role: SUB_INVESTIGATOR, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06262737, orgStudyIdInfo id: RBHP 2023 CHIAMBARETTA, secondaryIdInfos id: 2023-A01121-44, type: REGISTRY, domain: ANSM, briefTitle: Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol, acronym: PISO, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-30, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2025-10-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: University Hospital, Clermont-Ferrand, class: OTHER, descriptionModule briefSummary: The purpose of this study is to assess the sensation of ocular dry eye symptom after an intravitreal injection of anti-VEGF., conditionsModule conditions: Macular Degeneration, conditions: Diabetic Macular Edema, conditions: Retinal Vein Occlusion, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, outcomesModule primaryOutcomes measure: OSDI, secondaryOutcomes measure: OSDI, secondaryOutcomes measure: HM, secondaryOutcomes measure: AM, secondaryOutcomes measure: NIBUT 1, secondaryOutcomes measure: NIBUT 2, secondaryOutcomes measure: Interferometry, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHU de Clermont-Ferrand, status: RECRUITING, city: Clermont-Ferrand, zip: 63000, country: France, geoPoint lat: 45.77966, lon: 3.08628, hasResults: False
protocolSection identificationModule nctId: NCT06262724, orgStudyIdInfo id: Perforator Flaps, briefTitle: Breast Reshaping Following Massive Weight Loss, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-08-01, primaryCompletionDateStruct date: 2023-08-01, completionDateStruct date: 2024-01-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Ain Shams University, class: OTHER, descriptionModule briefSummary: Reliability of Chest Wall Perforator Flaps for Breast Reshaping following Massive Weight Loss, conditionsModule conditions: Breast Ptosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: All patients were subjected to the same intervention., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: Breast auto-augmentation, outcomesModule primaryOutcomes measure: Measurement of breast volume by sono-mammography, secondaryOutcomes measure: Sternal notch to nipple distance, secondaryOutcomes measure: Nipple to inframammary fold distance, secondaryOutcomes measure: Measure of nipple-to-nipple distance, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Medicine, Ain Shams University, city: Cairo, state: Abbasia, zip: 11591, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06262672, orgStudyIdInfo id: PR0319R01, briefTitle: Evaluation of Some Parameters in University Students During the COVİD-19 Epidemic Process, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-20, primaryCompletionDateStruct date: 2021-11-20, completionDateStruct date: 2021-11-20, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Kırklareli University, class: OTHER, descriptionModule briefSummary: The physical and mental effects of the COVID-19 pandemic have been examined by many researchers, but this study aims to evaluate in every aspect how university students who had to receive education with the distance education model due to the pandemic went through this process. Data regarding people's positive and negative habits from anthropometric characteristics and sleep quality, which is one of the sub-dimensions of healthy lifestyle behaviors, were evaluated, and the relationship between these parameters was examined in detail., conditionsModule conditions: Health Behavior, conditions: Sleep, conditions: Body Weight, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 236, type: ACTUAL, armsInterventionsModule interventions name: Evaluation form, outcomesModule primaryOutcomes measure: Health Promotion Life-Style Profile (HPLP-II), primaryOutcomes measure: Pittsburgh Sleep Quality Index (PSQI), primaryOutcomes measure: Anthropometric Measurements, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kirklareli University, city: Kirklareli, state: Kayalı, zip: 39000, country: Turkey, geoPoint lat: 41.73508, lon: 27.22521, hasResults: False
protocolSection identificationModule nctId: NCT06262659, orgStudyIdInfo id: 2023-142, briefTitle: The Effect of Ultrasonography on Blood Flow,Vessel Diameter,and Depth Measurements in Dialysis Patients With Fistula, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-08, primaryCompletionDateStruct date: 2024-06-10, completionDateStruct date: 2024-09-10, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Kudret Atakan Tekin, class: OTHER, descriptionModule briefSummary: Arteriovenous fistulas (AVF) are considered essential and the primary vascular access for end-stage renal disease patients to receive hemodialysis (HD) treatment. The maturation failure rate of AVFs is approximately 23%. The aim of our study is to compare intraoperative fistula flow and measurements of vascular structures' diameters with postoperative fistula maturation, following the completion of the fistula operation, to reveal the relationship between them. Providing insights into the need for intraoperative intervention and/or postoperative fistula management based on these measurements is intended to contribute to the literature by offering predictions and perspectives., conditionsModule conditions: Arteriovenous Fistula, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: Doppler Ultrasonography Assessment, outcomesModule primaryOutcomes measure: intraoperative Arteriovenous Fistula Flow Measurement, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kudret Atakan Tekin, status: RECRUITING, city: Merkez, state: Çorum, country: Turkey, contacts name: Kudret Atakan Tekin, role: CONTACT, phone: 05424912184, email: dr.kudretatakantekin@gmail.com, hasResults: False
protocolSection identificationModule nctId: NCT06262633, orgStudyIdInfo id: CRE-2023.079, briefTitle: A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-03-19, sponsorCollaboratorsModule leadSponsor name: Chinese University of Hong Kong, class: OTHER, descriptionModule briefSummary: This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial., conditionsModule conditions: Prostate Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 103, type: ESTIMATED, armsInterventionsModule interventions name: Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation, outcomesModule primaryOutcomes measure: The oncological control of prostate cancer, secondaryOutcomes measure: Cancer detection on biopsy of each ablated MRI visible lesion, secondaryOutcomes measure: Cancer detection on biopsy of each ablated MRI invisible lesion, secondaryOutcomes measure: Gleason 4 or 5 cancer detected on biopsy of ablated area, secondaryOutcomes measure: Out-of-field recurrence: Any cancer outside treated area on systematic biopsy, secondaryOutcomes measure: Common Terminology Criteria for Adverse Events (CTCAE) v5.0, secondaryOutcomes measure: PSA change, secondaryOutcomes measure: Urinary Symptoms after treatment, secondaryOutcomes measure: Sexual side effects after treatment, secondaryOutcomes measure: Continence side effects after treatment, secondaryOutcomes measure: Common Terminology Criteria for Adverse Events (CTCAE) rectal toxicity, secondaryOutcomes measure: Quality of life measured by ED-5Q-5Lquestionnaire, secondaryOutcomes measure: Quality of life in patients with prostate cancer measured by EPIC-26, secondaryOutcomes measure: Quality of life measured by QLQ-C30,, eligibilityModule sex: MALE, minimumAge: 45 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peter Ka-Fung CHIU, status: RECRUITING, city: Sha Tin, country: Hong Kong, contacts name: Peter Ka-Fung CHIU, PhD,MBChB, role: CONTACT, phone: 35052625, email: peterchiu@surgery.cuhk.edu.hk, geoPoint lat: 22.38333, lon: 114.18333, hasResults: False
protocolSection identificationModule nctId: NCT06262620, orgStudyIdInfo id: 2022-NHLHCRF-LX-01-0201-06, briefTitle: The Comparisonof Mediastinal/Hilar Lymph Node Biopsies by EBUS-TBNA, EBUS-TBCB, and EBUS-TBFB, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-18, primaryCompletionDateStruct date: 2026-02-18, completionDateStruct date: 2026-02-18, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: China-Japan Friendship Hospital, class: OTHER, descriptionModule briefSummary: The goal of this prospective, multi-centre, randomised controlled clinical study is to compare the diagnostic efficacy and safety of the three biopsy techniques (EBUS-TBNA, EBUS-TBCB, and EBUS-TBFB) in mediastinal/hilar lymph node biopsies.Participants will divided into EBUS-TBNA group, EBUS-TBCB group, and EBUS-TBFB group at a 1:1:1 ratio by using central, computerized random sequence, and then undertake EBUS-TBNA, EBUS-TBCB, or EBUS-TBFB according to the group.Researchers will compare the adequacy of sampling by the three biopsy techniques, their sample quality, diagnostic rate, and incidence of each adverse events., conditionsModule conditions: Lymphadenopathy Hilar, conditions: Lymphadenopathy Mediastinal, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 723, type: ESTIMATED, armsInterventionsModule interventions name: EBUS-TBNA, interventions name: EBUS-TBCB, interventions name: EBUS-TBFB, outcomesModule primaryOutcomes measure: Dignostic rate of EBUS-TBNA, EBUS-TBCB, and EBUS-TBFB, primaryOutcomes measure: Incidence rate of adverse events, primaryOutcomes measure: the adequacy of sample acquisition, primaryOutcomes measure: the quality of sample acquisition, eligibilityModule sex: ALL, minimumAge: 15 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06262607, orgStudyIdInfo id: CLE400-NP-201, briefTitle: A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-29, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-01-15, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Clexio Biosciences Ltd., class: INDUSTRY, descriptionModule briefSummary: This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with Notalgia Paresthetica (NP)., conditionsModule conditions: Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP), designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 40 subjects, 2 arms, parallel, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: double, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: CLE-400, interventions name: Vehicle, outcomesModule primaryOutcomes measure: Percent change from baseline in weekly mean of the daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) score at Week 4., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinical site 11, status: RECRUITING, city: Bryant, state: Arkansas, zip: 72022, country: United States, geoPoint lat: 34.59593, lon: -92.48905, locations facility: Clinical site 01, status: RECRUITING, city: Coral Gables, state: Florida, zip: 33134, country: United States, geoPoint lat: 25.72149, lon: -80.26838, locations facility: Clinical Site 10, status: RECRUITING, city: North Miami Beach, state: Florida, zip: 33116, country: United States, geoPoint lat: 25.93315, lon: -80.16255, locations facility: Clinical Site 02, status: RECRUITING, city: Indianapolis, state: Indiana, zip: 46250, country: United States, geoPoint lat: 39.76838, lon: -86.15804, locations facility: Clinical Site 23, status: RECRUITING, city: Methuen, state: Massachusetts, zip: 01844, country: United States, geoPoint lat: 42.7262, lon: -71.19089, locations facility: Clinical Site 09, status: RECRUITING, city: Dublin, state: Ohio, zip: 43016, country: United States, geoPoint lat: 40.09923, lon: -83.11408, locations facility: Clinical site 16, status: RECRUITING, city: Houston, state: Texas, zip: 77004, country: United States, geoPoint lat: 29.76328, lon: -95.36327, locations facility: Clinical Site 06, status: RECRUITING, city: San Antonio, state: Texas, zip: 78213, country: United States, geoPoint lat: 29.42412, lon: -98.49363, hasResults: False
protocolSection identificationModule nctId: NCT06262594, orgStudyIdInfo id: L'ÉTOILE, briefTitle: Lemborexant Treatment of Insomnia Linked to Epilepsy, acronym: L'ÉTOILE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-08, primaryCompletionDateStruct date: 2025-02-08, completionDateStruct date: 2026-02-08, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: University of Manitoba, class: OTHER, collaborators name: Duke University, descriptionModule briefSummary: The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy., conditionsModule conditions: Epilepsy, conditions: Sleep, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 26, type: ESTIMATED, armsInterventionsModule interventions name: Lemborexant, outcomesModule primaryOutcomes measure: WASO, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06262568, orgStudyIdInfo id: Soh-Med-23-03-18MS, briefTitle: Effect of Guidelines on Nurses' Awareness Toward HRP and Maternal Near Miss Cases, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-02-16, lastUpdatePostDateStruct date: 2024-02-16, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: The current study will evaluate the impact of awareness of maternity nurses toward instructional guidelines and evaluate the knowledge, practice and attitude of nurses toward high risk pregnancy and maternal near miss cases before and after education., conditionsModule conditions: High Risk Pregnancy and Maternal Near Miss Cases, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 71, type: ESTIMATED, armsInterventionsModule interventions name: assess the nurse knowledge and practices., outcomesModule primaryOutcomes measure: Evaluate the outcome of instructional guidelines on maternity nurses' awareness toward high-risk pregnancy and Maternal Near Miss Cases by questionnaire before and after training, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Sohag University hospitals, status: RECRUITING, city: Sohag, country: Egypt, contacts name: ghona Abd EL-Nasser, Professor, role: CONTACT, phone: 01123067894, email: mahmoud.hazem@nursing.sohag.edu.eg, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False